Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Mild to Moderate

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44358   clinical trials with a EudraCT protocol, of which   7384   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,419 result(s) found for: Mild to Moderate. Displaying page 68 of 71.
    «« First « Previous 63  64  65  66  67  68  69  70  71  Next»
    EudraCT Number: 2019-002186-36 Sponsor Protocol Number: DSC-BROMS-1 Start Date*: 2021-05-26
    Sponsor Name:Uppsala University Hospital
    Full Title: A multicenter, open-label, randomized, phase I/II clinical trial comparing safety and durable overall response rate (DOR) at 56 days in patients with steroid resistant severe acute GvHD after allog...
    Medical condition: Steroid refractory acute GVHD
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10068908 AGVHD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) NO (Trial now transitioned) DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-018621-19 Sponsor Protocol Number: MT-04 Start Date*: 2011-09-30
    Sponsor Name:ALK-Abelló A/S
    Full Title: Efficacy of ALK house dust mite allergy immunotherapy tablet in subjects with house dust mite induced asthma. The MITRA Trial.
    Medical condition: House dust mite induced allergic asthma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10001705 Allergic asthma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) DK (Completed) SK (Completed) LT (Completed) ES (Completed) GB (Completed) AT (Completed) NL (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2008-000826-37 Sponsor Protocol Number: AZ3110865 Start Date*: 2008-07-14
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: Study AZ3110865, a study comparing SB-742457 or donepezil versus placebo in subjects with mild-to-moderate Alzheimer’s disease
    Medical condition: Alzheimer's disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) EE (Completed) BG (Completed) DE (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2008-000095-25 Sponsor Protocol Number: DIM14 Start Date*: 2008-12-22
    Sponsor Name:Medivation, Inc.
    Full Title: CONNECTION: A Global Phase 3, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Oral Dimebon in Patients with Mild-to-Moderate Alzheimer’s Disease
    Medical condition: Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) FR (Completed) SE (Completed) DE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2015-002868-17 Sponsor Protocol Number: 633765 Start Date*: 2016-05-06
    Sponsor Name:Fundación Centro Nacional de Investigaciones Cardiovasculares, Carlos III (CNIC)
    Full Title: Secondary Prevention of Cardiovascular Disease in the Elderly
    Medical condition: Secondary Prevention of Major Cardiovascular Events (cardiovascular death, nonfatal myocardial infarction, nonfatal ischemic stroke, and urgent revascularization) in post MI cohort.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10028597 Myocardial infarction acute LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Ongoing) CZ (Completed) HU (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-004782-24 Sponsor Protocol Number: PRM-151-202 Start Date*: 2016-03-01
    Sponsor Name:Promedior, Inc.
    Full Title: A Phase 2 Trial to Evaluate the Efficacy of PRM-151 in Subjects with Idiopathic Pulmonary Fibrosis (IPF)
    Medical condition: Idiopathic Pulmonary Fibrosis (IPF)
    Disease: Version SOC Term Classification Code Term Level
    18.1 10038738 - Respiratory, thoracic and mediastinal disorders 10021240 Idiopathic pulmonary fibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) CZ (Completed) ES (Completed) HU (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-003639-41 Sponsor Protocol Number: UP0089 Start Date*: 2020-11-06
    Sponsor Name:UCB Biopharma SRL
    Full Title: Phase 1/2A, randomized, placebo-controlled, single-ascending dose (Part A, participant- and investigator-blind) and repeated-dose (Part B, participant-, investigator-, and sponsor-blind) study to i...
    Medical condition: Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) NL (Completed) BG (Completed) DE (Completed) ES (Ongoing) BE (Completed)
    Trial results: View results
    EudraCT Number: 2014-000217-30 Sponsor Protocol Number: 3098012 Start Date*: 2015-06-16
    Sponsor Name:Orion Corporation
    Full Title: EFFICACY OF ORM-12741 ON AGITATION/AGGRESSION SYMPTOMS IN PATIENTS WITH ALZHEIMER’S DISEASE: A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTICENTRE STUDY OF 12 WEEKS
    Medical condition: The agitation/aggression symptoms in patients with Alzheimer’s disease
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) FI (Completed) PL (Completed) BG (Completed) RO (Suspended by CA) HR (Completed)
    Trial results: View results
    EudraCT Number: 2009-017044-13 Sponsor Protocol Number: SPD476-409 Start Date*: 2010-06-30
    Sponsor Name:Shire Development LLC
    Full Title: A Phase 3b/4, Open-label, Multicenter, Prospective Study to Evaluate the Effect of Remission Status on the Ability to Maintain or Achieve Clinical and Endoscopic Remission During a 12-Month, Long...
    Medical condition: Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) IE (Completed) HU (Completed) BE (Completed) CZ (Completed) DE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2016-002584-33 Sponsor Protocol Number: CINC424C2301 Start Date*: 2017-01-23
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase III randomized open-label multi-center study of ruxolitinib vs. best available therapy in patients with corticosteroid-refractory acute graft vs. host disease after allogenic stem cell tran...
    Medical condition: corticosteroid-refractory acute graft vs. host disease after allogeneic stem cell transplantation
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021428 - Immune system disorders 10066260 Acute graft versus host disease PT
    20.1 10021428 - Immune system disorders 10066262 Acute graft versus host disease in skin PT
    20.1 10021428 - Immune system disorders 10066264 Acute graft versus host disease in intestine PT
    20.1 10021428 - Immune system disorders 10066263 Acute graft versus host disease in liver PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) ES (Completed) AT (Completed) FR (Completed) NO (Completed) SE (Completed) DK (Completed) GB (GB - no longer in EU/EEA) CZ (Completed) PT (Completed) HU (Completed) BG (Completed) PL (Completed) NL (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2020-004805-30 Sponsor Protocol Number: CLN-PXT3003-06 Start Date*: Information not available in EudraCT
    Sponsor Name:Pharnext SCA
    Full Title: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Assess the Efficacy, Safety, and Tolerability of PXT3003 in Charcot-Marie-Tooth type 1A (CMT1A)
    Medical condition: Charcot Marie Tooth Type 1A
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10008414 Charcot-Marie-Tooth disease LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) BE (Completed) NL (Prematurely Ended) DK (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended) FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-002735-26 Sponsor Protocol Number: CC-10004-PSA-013 Start Date*: 2019-04-16
    Sponsor Name:Amgen Inc.
    Full Title: A PHASE 4, MULTICENTER, RANDOMIZED, DOUBLEBLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF APREMILAST (CC-10004) IN SUBJECTS WITH EARLY, OLIGOARTICULAR PSORIAT...
    Medical condition: EARLY, OLIGOARTICULAR PSORIATIC ARTHRITIS
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Restarted) FR (Prematurely Ended) ES (Ongoing) BE (Completed) NL (Completed) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2022-000995-21 Sponsor Protocol Number: CABL001J12302 Start Date*: 2022-09-19
    Sponsor Name:Novartis Pharma AG
    Full Title: A phase IIIb, multi-center, open-label, randomized study of tolerability and efficacy of oral asciminib versus nilotinib in patients with newly diagnosed Philadelphia Chromosome Positive Chronic My...
    Medical condition: Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia in chronic phase (CML-CP) in newly diagnosed patients
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10009012 Chronic myelogenous leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) HU (Trial now transitioned) SK (Trial now transitioned) CZ (Trial now transitioned) IT (Trial now transitioned) NL (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-004056-37 Sponsor Protocol Number: MV40618 Start Date*: 2019-10-17
    Sponsor Name:Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd
    Full Title: A PHASE IIIB, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CLINICAL EFFICACY STUDY OF BALOXAVIR MARBOXIL FOR THE REDUCTION OF DIRECT TRANSMISSION OF INFLUENZA FROM OTHERWISE HEALTHY P...
    Medical condition: Influenza
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10022001 Influenza (epidemic) LLT
    20.1 100000004862 10022003 Influenza B virus infection LLT
    20.1 100000004862 10022002 Influenza A virus infection LLT
    20.0 100000004862 10016790 Flu LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Temporarily Halted) GB (GB - no longer in EU/EEA) GR (Completed) HU (Completed) PL (Completed) FR (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2020-004643-80 Sponsor Protocol Number: DS1062-A-U301 Start Date*: 2021-03-10
    Sponsor Name:Daiichi Sankyo, Inc.
    Full Title: Phase 3 Randomized Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer without Actionable Genomic Alterations
    Medical condition: Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) HU (Completed) DE (Trial now transitioned) BE (Trial now transitioned) NL (Trial now transitioned) CZ (Completed) IT (Trial now transitioned)
    Trial results: View results
    EudraCT Number: 2010-021155-11 Sponsor Protocol Number: H8A-MC-LZAO Start Date*: 2010-11-29
    Sponsor Name:Eli Lilly and Company
    Full Title: Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid β Antibody in Patients with Alzheimer’s Disease
    Medical condition: Alzheimer's disease
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) ES (Completed) IT (Completed) SE (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-003960-20 Sponsor Protocol Number: NN7008-3543 Start Date*: 2009-06-26
    Sponsor Name:Novo Nordisk A/S
    Full Title: A Multi-Centre, Open-Label, Non-Controlled Trial on Safety and Efficacy of N8 in Prevention and Treatment of Bleeds in Previously Treated Subjects with Haemophilia A Sub-Trial: Safety and Efficacy ...
    Medical condition: Haemophilia A
    Disease: Version SOC Term Classification Code Term Level
    13.1 10010331 - Congenital, familial and genetic disorders 10018937 Haemophilia A LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male
    Trial protocol: DE (Completed) GB (Completed) ES (Completed) IT (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2009-011931-11 Sponsor Protocol Number: H 552 000 - 0911 Start Date*: Information not available in EudraCT
    Sponsor Name:Almirall Hermal GmbH
    Full Title: Explorative, double-blind, randomized, controlled multi-center phase II study to evaluate the efficacy and safety of topically applied combinational product LAS41003 once daily versus corresponding...
    Medical condition: Patients aged 18 and older suffering from at least one clinically diagnosed superinfected or impetiginised eczema such as e.g. • superinfected or impetiginised atopic eczema • superinfected or impe...
    Disease: Version SOC Term Classification Code Term Level
    12.0 10021773 Infected eczema LLT
    12.0 10014184 Eczema LLT
    12.0 10014188 Eczema allergic LLT
    12.0 10014191 Eczema atopic LLT
    12.0 10014199 Eczema infected LLT
    12.0 10014201 Eczema nummular LLT
    12.0 10051890 Eczema impetiginous LLT
    12.0 10000618 Actinic reticuloid-photosensitive eczema LLT
    12.0 10001712 Allergic eczema LLT
    12.0 10003641 Atopic eczema LLT
    12.0 10010803 Contact eczema LLT
    12.0 10014206 Eczematous dermatitis LLT
    12.0 10021773 Infected eczema LLT
    12.0 10049706 Eczematous dermatitis infected LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-004789-17 Sponsor Protocol Number: RD.06.SPR.203065 Start Date*: 2020-07-08
    Sponsor Name:Galderma S.A.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects with Prurigo Nodularis
    Medical condition: Prurigo Nodularis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10037084 Prurigo nodularis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed) NL (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2022-002321-10 Sponsor Protocol Number: PR11/2022 Start Date*: 2023-01-16
    Sponsor Name:Hospital Universitari d'Igualada
    Full Title: Effectiveness and safety of topical sevoflurane for the treatment of painful skin ulcers; randomized, double-blind, placebo-controlled clinical trial
    Medical condition: Cutaneous complex ulcers (grade II, III and IV) which are painful and require hospital care
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10065043 CMV mucocutaneous ulcer LLT
    21.0 100000004858 10045334 Ulcer skin LLT
    20.0 100000004858 10016980 Foot ulcer LLT
    20.0 100000004858 10077779 Pressure ulcer LLT
    21.0 100000004858 10077409 Ischemic skin ulcer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 63  64  65  66  67  68  69  70  71  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Sep 03 21:50:11 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA